These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 35716099)
21. Skin cancer in organ transplant recipients: more than the immune system. Wheless L; Jacks S; Mooneyham Potter KA; Leach BC; Cook J J Am Acad Dermatol; 2014 Aug; 71(2):359-65. PubMed ID: 24725477 [TBL] [Abstract][Full Text] [Related]
22. Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study. Préterre J; Visentin J; Saint Cricq M; Kaminski H; Del Bello A; Prezelin-Reydit M; Merville P; Kamar N; Couzi L Clin Transplant; 2021 Mar; 35(3):e14207. PubMed ID: 33369772 [TBL] [Abstract][Full Text] [Related]
23. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Ritchie SA; Patel MJ; Miller SJ Dermatol Surg; 2012 Oct; 38(10):1604-21. PubMed ID: 22646842 [TBL] [Abstract][Full Text] [Related]
25. Capecitabine for skin cancer prevention in solid organ transplant recipients. Jirakulaporn T; Endrizzi B; Lindgren B; Mathew J; Lee PK; Dudek AZ Clin Transplant; 2011; 25(4):541-8. PubMed ID: 21050273 [TBL] [Abstract][Full Text] [Related]
26. Synergism between mTOR pathway and ultraviolet radiation in the pathogenesis of squamous cell carcinoma and its implication for solid-organ transplant recipients. Balagula Y; Kang S; Patel MJ Photodermatol Photoimmunol Photomed; 2015 Jan; 31(1):15-25. PubMed ID: 24517835 [TBL] [Abstract][Full Text] [Related]
27. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469 [TBL] [Abstract][Full Text] [Related]
28. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients. Herman S; Rogers HD; Ratner D Skinmed; 2007; 6(5):234-8. PubMed ID: 17786101 [TBL] [Abstract][Full Text] [Related]
29. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis. Gu YH; Du JX; Ma ML Asian Pac J Cancer Prev; 2012; 13(9):4335-9. PubMed ID: 23167339 [TBL] [Abstract][Full Text] [Related]
30. Nonmelanoma skin cancer mortality (1988-2000): the Rhode Island follow-back study. Lewis KG; Weinstock MA Arch Dermatol; 2004 Jul; 140(7):837-42. PubMed ID: 15262694 [TBL] [Abstract][Full Text] [Related]
32. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients. Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126 [TBL] [Abstract][Full Text] [Related]
33. Skin Cancer in Non-White Solid Organ Transplant Recipients: Mayo Clinic Experience. Zieman D; Heckman M; Brushaber D; Degesys C; Tolaymat L South Med J; 2023 Oct; 116(10):839-844. PubMed ID: 37788820 [TBL] [Abstract][Full Text] [Related]
34. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient. Signorell J; Hunziker T; Martinelli M; Koestner SC; Mohacsi PJ Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874 [TBL] [Abstract][Full Text] [Related]
35. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. O'Reilly Zwald F; Brown M J Am Acad Dermatol; 2011 Aug; 65(2):253-261. PubMed ID: 21763561 [TBL] [Abstract][Full Text] [Related]
36. Use of Mammalian Target of Rapamycin Inhibitors for Pancreas Transplant Immunosuppression Is Associated With Improved Allograft Survival and Improved Early Patient Survival. Siskind EJ; Liu C; Collins DT; Emery E; Steen E; Tran E; Stodghill J; Piper J; Jonsson J; Ortiz J Pancreas; 2019; 48(5):644-651. PubMed ID: 31091210 [TBL] [Abstract][Full Text] [Related]
38. Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist. Berman H; Shimshak S; Reimer D; Brigham T; Hedges MS; Degesys C; Tolaymat L Mayo Clin Proc; 2022 Dec; 97(12):2355-2368. PubMed ID: 36334939 [TBL] [Abstract][Full Text] [Related]
39. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Opelz G; Unterrainer C; Süsal C; Döhler B Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384 [TBL] [Abstract][Full Text] [Related]
40. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Willey A; Mehta S; Lee PK Dermatol Surg; 2010 May; 36(5):652-8. PubMed ID: 19889154 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]